Document Detail

Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis.
MedLine Citation:
PMID:  17538803     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To compare the efficacy and safety of tacrolimus ointment 0.1% and pimecrolimus cream 1% in adult patients with moderate to very severe atopic dermatitis (AD). METHODS: A total of 281 patients (141 treated with tacrolimus and 140 treated with pimecrolimus) were randomized to a multicenter, investigator-blinded, 6-week study. RESULTS: Tacrolimus-treated patients had significantly greater improvements in the Eczema Area Severity Index score compared with pimecrolimus-treated patients (mean percent reduction from baseline to study end: 57% vs 39%, respectively; p=0.0002). Treatment success was also significantly greater among the tacrolimus-treated patients compared with pimecrolimus-treated patients (40% vs 22% at study end; p=0.001), as was the improvement in percentage of total body surface area affected (a reduction of 49% vs 34% at study end; p=0.01). Both treatment groups had similar improvements in patient assessment of itch. There were no significant differences in the incidences of adverse events, including application-site burning and application-site pruritus, the two most commonly reported adverse events. Significantly more pimecrolimus-treated patients than tacrolimus-treated patients withdrew from the study due to lack of efficacy (10 vs 1, p=0.005). CONCLUSION: Tacrolimus ointment is more effective than pimecrolimus cream in adults with moderate to very severe AD. Both agents have a similar safety profile.
Alan B Fleischer; William Abramovits; Debra Breneman; Eileen Jaracz;
Related Documents :
17085943 - Pimecrolimus cream 1% in the treatment of lichen sclerosus.
25276413 - Subthreshold micropulse photocoagulation for persistent macular edema secondary to bran...
16880243 - Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bon...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of dermatological treatment     Volume:  18     ISSN:  0954-6634     ISO Abbreviation:  J Dermatolog Treat     Publication Date:  2007  
Date Detail:
Created Date:  2007-05-31     Completed Date:  2007-07-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8918133     Medline TA:  J Dermatolog Treat     Country:  England    
Other Details:
Languages:  eng     Pagination:  151-7     Citation Subset:  IM    
Wake Forest University, Winston-Salem, NC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Cutaneous
Dermatitis, Atopic / drug therapy*,  pathology
Double-Blind Method
Immunologic Factors / administration & dosage,  therapeutic use*
Prospective Studies
Severity of Illness Index
Tacrolimus / administration & dosage,  analogs & derivatives*,  therapeutic use*
Treatment Outcome
United States
Reg. No./Substance:
0/Immunologic Factors; 0/Ointments; 0/pimecrolimus; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pimecrolimus, yet another intriguing topical immunomodulator.
Next Document:  Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals w...